A San Diego biopharmaceutical company developing antibody-based medicines for solid-tumor cancers. Its signature Conditionally Active Biologics (CAB) platform engineers antibodies to stay switched off in healthy tissue and only wake up in the acidic environment of a tumor, sparing healthy cells. Founded in 2007 by biotech veteran Jay Short and Carolyn Anderson, the firm's name plays on that same idea—antibodies that act only under certain conditions.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +83.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.